Nexalin Technology, Inc. Common Stock
NXLStock
$0.45−60.18%52W
Market Cap$10.32M
P/E—
Div yield—
Beta4.03
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-54.89%
Price vs S&P 500 (4W)1.81%
VGM Score32.64
Market Capitalization$10.32M
Earnings Surprise History
Q1 26-0.11est. -0.10
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
4.00
Industry Peers — Electromedical Equipment(32)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NXLNexalin Technology, Inc. Common Stock | F | C | D | $0.45 |
| MDTMedtronic plc | B | C | C | $83.56 |
| MASIMasimo Corporation | D | D | C | $179.95 |
| LIVNLivaNova PLC Ordinary Shares | C | C | B | $81.79 |
| ITGRInteger Holdings Corporation | B | C | B | $99.62 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | $76.00 |
| AXGNAxogen, Inc. Common Stock | F | B | B | $39.77 |
| BLFSBioLife Solutions Inc. | F | B | A | $30.26 |
| CNMDCONMED Corporation | A | C | B | $45.01 |
| INMDInMode Ltd. Ordinary Shares | A | D | B | $15.60 |
| CBLLCeriBell, Inc. Common Stock | D | A | C | $19.14 |
About
Nexalin Technology develops bioelectronic neurostimulation devices for treating anxiety and insomnia without medications or psychotherapy. The company's Generation 1 product is a cranial electrotherapy stimulation (CES) device that delivers targeted neural stimulation. As a Class II FDA-cleared device, it represents a non-pharmacological treatment option in the mental health care market.